Increasingly scary headlines about Middle Eastern Respiratory Syndrome (MERS) and a possible pandemic have proliferated around the Internet.
The natural question for any investor to ask is this: There could definitely be a need for a vaccine. Is there some company developing a vaccine I can invest in?
Three quick thoughts in answer to that question:
First: There really aren't any great MERS vaccine makers to invest in. Now, there are companies developing MERS vaccines...but their drugs are mostly preclinical in nature (either they're being tested in mice, or they've just completed that step). It's hard to know whether the drugs have a reasonable shot at success, since they haven't been tested in humans and are at the beginning of what will likely be a long trek toward regulatory approval.
Second: There are some great vaccine makers out there that investors could consider instead: Sanofi (NYSE:SNY) and GlaxoSmithKline (NYSE:GSK). They are large, diversified companies with interesting pipelines (more on that in the video).
And third: Wash your hands.
In this video, from Where The Money Is, the Motley Fool's investing show, health care analysts Michael Douglass and David Williamson lay out some additional thoughts on these topics.
Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.